Prior to joining Avalere, Dr. Fifer founded and managed the Technology Assessment Group (TAG), a leading outcomes research firm that assessed the value of innovative medical technologies and interventions. After selling TAG, she maintained five of its offices in the U.S., Canada, and the U.K. Since then, Dr. Fifer has maintained an active consulting practice working with provider organizations, such as University of California, Los Angeles Health; serving as senior advisor to the Network for Excellence in Health Innovation; and serving as an expert panel member for the California Blue Shield Foundation’s California Technology Assessment Forum. She is a member of Mercer-Marsh’s National Panel of Senior Healthcare Advisors. Dr. Fifer also has expertise in consulting with providers, life sciences manufacturers, and venture capitalist firms in strategic planning, and product valuation as well as for wellness firms in patient support services.
Prior to her work at Avalere, Richner founded and later sold The Neocure Group, a company providing data analytics, health economics, and reimbursement strategic services for biotech, technology, and pharmaceutical industry and investors to Intralign, LLC. For Intralign, she served as executive vice president, managing the transition to a provider-based service company and overseeing analytic services and reimbursement support to hospitals. Previously, she was vice president of Global Government Affairs and Reimbursement at Boston Scientific Corporation, where she established the global reimbursement and economics function, expanding to national and international medical device legislative and regulatory, tax, and trade issues. She currently serves on the Executive Dean's Advisory Board at the University of Michigan’s School of Public Health and on the board of Massachusetts Medical Device Industry Council (MassMEDIC) where she founded the MassMEDIC Women in Medtech.